ASO Author Reflections: The Diminishing Role of Adjuvant HIPEC

  • Laura M. Enomoto
  • Perry ShenEmail author
ASO Author Reflections



Laura M. Enomoto and Perry Shen report no conflicts of interest.


  1. 1.
    Glehen O, Passot G, Villeneuve L, et al. GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study. BMC Cancer. 2014;14:183.CrossRefGoogle Scholar
  2. 2.
    Klaver CE, Wisselink DD, Punt CJ, et al. Adjuvant HIPEC in patients with colon cancer at high risk of peritoneal metastases: primary outcome of the COLOPEC multicenter randomized trial. J Clin Oncol. 2019;37(4 Suppl):482.CrossRefGoogle Scholar
  3. 3.
    Goere D, Glehen O, Quenet F, et al. Results of a randomized phase 3 study evaluating the potential benefit of a second-look surgery plus HIPEC in patients at high risk of developing colorectal peritoneal metastases. J Clin Oncol. 2018;36(15 Suppl):3531.CrossRefGoogle Scholar
  4. 4.
    Enomoto LM, Choudry MH, Bartlett DL, et al. Outcomes after adjuvant hyperthermic intraperitoneal chemotherapy for high-risk primary appendiceal neoplasms after complete resection. Ann Surg Oncol. Epub 31 Jul 2019.
  5. 5.
    Quenet F, Elias D, Roca L, et al. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J Clin Oncol. 2018;36(18 Suppl):3503.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  1. 1.Department of SurgeryWake Forest Baptist Medical CenterWinston-SalemUSA

Personalised recommendations